69 completed. 69 Phase 2, 23 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 69 | Completed 69 |
| Phase 1 | 23 | Completed 23 |
| Phase 3 | 1 | Completed 1 |
Follow bendamustine: new trials by email Literature Review of bendamustine trials Research Report on bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) favezelimab/pembrolizumab, bendamustine, gemcitabine - Hodgkin Lymphoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 203 | 2022-10-18 | 2026-09-01 |
| AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma AB-101, Rituximab, Interleukin-2 - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Artiva Biotherapeutics, Inc. | 45 | 2021-03-29 | 2026-04-03 |
| Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age Venetoclax, Bendamustine, Rituximab - Mantle Cell Lymphoma | Phase 2 | Completed | PrECOG, LLC. | 33 | 2020-01-13 | 2025-08-11 |
| Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL Bendamustine, Obinutuzumab, Acalabrutinib - Chronic Lymphoid Leukemia | Phase 2 | Completed | German CLL Study Group | 46 | 2019-01-14 | 2024-12-30 |
| Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Bendamustine, Rituximab, Acalabrutinib - Mantle Cell Lymphoma | Phase 2 | Completed | Washington University School of Medicine | 13 | 2018-11-29 | 2026-04-21 |
| Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Bendamustine, Gemcitabine, Nivolumab - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Emory University | 3 | 2018-11-26 | 2025-08-06 |
| Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia Bendamustine, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Nicole Lamanna | 42 | 2018-11-12 | 2026-10-07 |
| First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years Obinutuzumab, Bendamustine - Indolent Non-hodgkin Lymphoma | Phase 2 | Completed | Prof. Dr. Wolfgang Hiddemann | 46 | 2017-12-12 | 2023-03-31 |
| The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD Bendamustine, Gemcitabine, Dexamethasone - Hodgkin's Lymphoma | Phase 2 | Completed | Polish Lymphoma Research Group | 115 | 2017-11-06 | 2025-01-16 |
| Bendamustine and Melphalan in Myeloma Melphalan, Bendamustine - Multiple Myeloma | Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 120 | 2017-07-20 | 2025-01-30 |
| A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment Nivolumab, brentuximab vedotin, bendamustine - Hodgkin Disease | Phase 2 | Completed | Bristol-Myers Squibb | 72 | 2017-03-28 | 2025-02-10 |
| GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Allogeneic stem cell transplantation, Fludarabine monophosphate, Busulfan - Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 27 | 2016-06-01 | 2020-11-23 |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia Durvalumab, Lenalidomide, Rituximab - Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 / Phase 2 | Completed | Celgene | 106 | 2016-05-11 | 2023-11-18 |
| Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) Bendamustine, Ofatumumab, Ibrutinib - Chronic Lymphocytic Leukemia | Phase 2 | Completed | German CLL Study Group | 66 | 2016-02-04 | 2020-06-11 |
| Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient Adcetris-Levact - Clinical Efficacy, Safety | Phase 1 / Phase 2 | Completed | Centre Antoine Lacassagne | 60 | 2016-01-14 | 2026-08-31 |
| A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) Atezolizumab, Bendamustine, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Lymphoma Follicular | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 91 | 2015-12-22 | 2021-05-24 |
| Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin Bendamustine, Prednisone, Vinblastine - Classical Hodgkin Lymphoma | Phase 2 | Completed | The Lymphoma Academic Research Organisation | 90 | 2015-07-17 | 2021-02-21 |
| Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG) Bendamustine, GA101, CAL-101 - Chronic Lymphocytic Leucemia | Phase 2 | Completed | German CLL Study Group | 48 | 2015-05-28 | 2024-05-09 |
| Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) Bendamustine, GA101, ABT-199 - Chronic Lymphocytic Leucemia | Phase 2 | Completed | German CLL Study Group | 66 | 2015-05-06 | 2025-06-10 |
| Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide - Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Kite, A Gilead Company | 307 | 2015-04-21 | 2024-06-04 |
Showing 20 of 69. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (16) · Lymphoma (14) · Lymphoma, Non-Hodgkin (12) · Hodgkin Disease (11) · Multiple Myeloma (10) · Lymphoma, Large B-Cell, Diffuse (8) · Recurrence (8) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (6) · Leukemia (5) · Leukemia, B-Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Breast Neoplasms (2) · Hematologic Diseases (2) · Immune System Diseases (2)
German CLL Study Group (6) · Hoffmann-La Roche (4) · SCRI Development Innovations, LLC (3) · Arbeitsgemeinschaft medikamentoese Tumortherapie (2) · Cephalon (2) · Columbia University (2) · French Innovative Leukemia Organisation (2) · M.D. Anderson Cancer Center (2) · Novartis Pharmaceuticals (2) · Seagen Inc. (2) · University of Wisconsin, Madison (2) · Weill Medical College of Cornell University (2) · Aptevo Therapeutics (1) · Artiva Biotherapeutics, Inc. (1) · Azienda Ospedaliera di Bolzano (1)
United States (44) · Germany (16) · France (11) · Canada (10) · Italy (10) · Poland (7) · Spain (7) · United Kingdom (6) · Australia (5) · Belgium (5) · Czechia (4) · Israel (4) · Netherlands (4) · Austria (3) · Russia (3)
Paula Cramer, Dr. med. (3) · Julie Chang, MD (2) · Richard Greil, Prof.Dr. (2) · Agostino Cortelezzi, Pr. (1) · Ajay Gopal (1) · Beth Christian, MD (1) · Boris V. Afanasyev, Professor (1) · Brad S Kahl, M.D. (1) · Clemens M. Wendtner (1) · Craig Portell, MD (1) · Frederick Lansigan, MD (1)
PMID 38620092, PMID 34086865, PMID 19860608, PMID 21239695, PMID 21844497, PMID 22869884, PMID 23109692, PMID 23430121, PMID 23955074, PMID 24359243, PMID 25911554, PMID 26331432, PMID 26377597, PMID 26913697, PMID 27222473, PMID 29038340, PMID 29226797, PMID 29276022, PMID 29703778, PMID 30518502, PMID 30568174, PMID 31073022, PMID 31190006, PMID 31693429, PMID 32083996, PMID 32107341, PMID 32705923, PMID 32770353, PMID 32785666, PMID 33028076, PMID 33035333, PMID 33243049, PMID 33334730, PMID 33448893, PMID 33586581, PMID 34296427, PMID 34310745, PMID 34493319, PMID 34515338, PMID 34691243, PMID 34749395, PMID 35086141, PMID 35359000, PMID 35594173, PMID 35852004, PMID 35988545, PMID 36287231, PMID 36564047, PMID 36821768, PMID 37946283
2014 (6), 2015 (3), 2016 (2), 2005 (1), 2023 (1), K12CA076930 (1), P30CA138292 (1)